This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
phttp://www.wikidata.org/prop/
wikibasehttp://wikiba.se/ontology#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1038/
n13http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q71169983
rdf:type
wikibase:Item
schema:description
article scientifique publié en 1996 artículu científicu espublizáu en xunetu de 1996 wetenschappelijk artikel im Juli 1996 veröffentlichter wissenschaftlicher Artikel наукова стаття, опублікована в липні 1996 scientific article published on 01 July 1996
p:P577
wds:Q71169983-107F39D5-E386-44B0-836A-DC583380B800
wdt:P577
1996-07-01T00:00:00Z
p:P2888
wds:Q71169983-282FBBF2-F2E2-403A-8146-F999327F5C2F
wdt:P2888
n10:nm0796-811
p:P2860
wds:Q71169983-BF4B4687-079F-4DA7-A810-682C0338C86C wds:Q71169983-DCD43E75-6286-4C29-8D24-DE3F97349207 wds:Q71169983-B0FBFE42-358B-4BC3-B816-35BB3E6DA5D9 wds:Q71169983-BE070E63-9F3F-44D1-B59B-91C60FA226CE wds:Q71169983-92E90F5D-7D76-4324-B75C-B3829F217E62 wds:Q71169983-9C9EABC1-0B13-48B8-8C06-AE134CE4771C wds:Q71169983-5D2FA70D-1CEF-45B1-944A-8D179F16F07D wds:Q71169983-6FC73683-B70C-4176-89C7-4C9CBD58DF67 wds:Q71169983-E6284C85-B925-4EBD-B378-1D154B6C9012
wdt:P2860
wd:Q44964668 wd:Q40739570 wd:Q72839445 wd:Q70537331 wd:Q71563602 wd:Q41673523 wd:Q29615031 wd:Q40484988 wd:Q53968484
p:P2093
wds:Q71169983-C21E91F9-F4D4-4C65-A853-BCCFFFBE67D3
wdt:P2093
B Smith-Sørensen
rdfs:label
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
skos:prefLabel
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
schema:name
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
p:P50
wds:Q71169983-F24A7B06-B13E-4F48-8137-94DD298B9C84 wds:Q71169983-730A222D-9A48-4309-8D3F-CA828B2B3D4C wds:Q71169983-B4F1A16A-012B-42F4-9E04-28C48EC2A4B9 wds:Q71169983-B6E6286C-FA66-4102-8E70-0723DF71F838 wds:Q71169983-3254A3EA-0FAD-40C0-82EB-F12DB303AC33 wds:Q71169983-E2EA7244-B65E-4629-924D-13B196217BAD wds:Q71169983-E8D9F794-E7CF-4900-AB04-BB7029047DDB
wdt:P50
wd:Q73630710 wd:Q17113533 wd:Q11983239 wd:Q74173735 wd:Q11958220 wd:Q11995192 wd:Q75952058
p:P1476
wds:Q71169983-16340A6C-C1E7-4EDA-86F4-E19B85020344
wdt:P1476
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
p:P304
wds:Q71169983-090E899D-05F9-470C-82D7-2F390E1CCEC3
wdt:P304
811-814
p:P31
wds:Q71169983-DAE4B9F4-EFB8-4B69-926D-93E6A1816585
wdt:P31
wd:Q13442814
p:P921
wds:Q71169983-35AF2918-6713-4A27-A5FC-720B1119DE13 wds:Q71169983-F03A0C0F-7EC1-42F9-B291-9E943EE76207
wdt:P921
wd:Q128581 wd:Q18936
p:P698
wds:Q71169983-3BF05F50-44B1-4457-8A12-9CBBC87A56E0
wdtn:P698
n13:8673929
wdt:P698
8673929
p:P1433
wds:Q71169983-1F940DD6-34F0-4778-9FE3-80DAE66FE01B
wdt:P1433
wd:Q1633234
p:P433
wds:Q71169983-85C81CA5-92E6-459B-AA7B-C020B90C7A54
p:P478
wds:Q71169983-1B92DDC5-C0DA-4F5E-B80D-A9B5E495FAC3
wdt:P433
7
wdt:P478
2
p:P356
wds:Q71169983-272B4C12-443E-4C10-9FD5-52A593B04617
wdtn:P356
n12:NM0796-811
wdt:P356
10.1038/NM0796-811